Clinical trials: Stage II Skin Cancer
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01632332
- Testing
- HER-2/neu peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination…
- Conditions
- Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06827236
- Testing
- BNT323, BNT327
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 380 people
- Sponsor
- BioNTech SE
Melanoma (Skin), Metastatic Cancer
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic radiosurgery may kill more tumor cells.
- Trial name
- NCT00003911
- Testing
- stereotactic radiosurgery
- Where
- 86 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Breast Carcinoma
Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction
Hypofractionated radiotherapy could provide more convenient treatment and had similar toxicities.However,reports of hypofractionated radiotherapy with two-stage expander/implant reconstruction are rare,Some studies have shown…
- Trial name
- NCT05045287
- Testing
- hypofractionated radiotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Cognitive/Functional Effects
Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98
RATIONALE: Studying cognitive function, such as thinking, attention, concentration, and memory, in postmenopausal women receiving hormone therapy for breast cancer may help improve quality of life and the ability to plan…
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Fatigue, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00343616
- Testing
- cognitive assessment, fatigue assessment and management, psychologic distress
- Where
- 12 sites in Australia, Belgium and 4 more
- Volunteers
- 135 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.
- Trial name
- NCT06452706
- Testing
- TQB2102 for injection
- Where
- 16 sites in China
- Volunteers
- 42 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00088998
- Testing
- bevacizumab, capecitabine, docetaxel
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Breast Cancer Metastatic
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
This study evalues the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring…
- Trial name
- LUZERN (NCT04240106)
- Testing
- Niraparib, Aromatase Inhibitors
- Where
- 10 sites in Spain
- Volunteers
- 14 people
- Sponsor
- MedSIR
Breast Cancer
Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer
RATIONALE: Diagnostic procedures such as sentinel lymph node biopsy may improve the ability to detect breast cancer and determine the extent of disease.
- Trial name
- NCT00005821
- Testing
- patent blue V dye, conventional surgery, lymphangiography
- Where
- 4 sites in United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma, Metastatic Melanoma
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF…
- Trial name
- NCT01495988
- Testing
- Vemurafenib, Bevacizumab, Cobimetinib
- Where
- 14 sites in United States
- Volunteers
- 10 people
- Sponsor
- Melanoma Research Foundation Breakthrough Consortium
Breast Cancer
Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer
The purpose of this study is to determine whether neo-adjuvant weekly paclitaxel with carboplatin is better than paclitaxel alone in efficiency and safety in early breast cancer, and to explore whether ultrasound and magnetic…
- Trial name
- NCT00919880
- Testing
- carboplatin+ paclitaxel, paclitaxel
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Tao OUYANG
Melanoma
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
This research study is testing the "chemo-switch" strategy in melanoma, using biochemotherapy initially to shrink tumors and then switching to daily low-dose chemotherapy (temozolomide) together with sorafenib.
- Trial name
- NCT00673361
- Testing
- Concurrent decrescendo biochemotherapy regimen, Low-dose Temozolomide plus Sorafenib
- Volunteers
- 9 people
- Sponsor
- Duke University
Melanoma
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
- Trial name
- NCT01200342
- Testing
- Genasense, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estrogen can stimulate the growth of breast cancer cells.
- Trial name
- NCT00963729
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 5 sites in South Korea, United Kingdom
- Volunteers
- 756 people
- Sponsor
- Imperial College London
Melanoma
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy.
- Trial name
- NCT00658437
- Testing
- CY-503
- Where
- 4 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Cytavis Biopharma GmbH
Melanoma
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
- Trial name
- NCT02155322
- Testing
- Pegylated Interferon Alfa-2b
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
This study evaluates efficacy of TAK- 228 and TAK- 117 followed by cisplatin and nab paclitaxel in patients with metastatic triple negative breast cancer.
- Trial name
- NCT03193853
- Testing
- Tak-228 & Tak-117, Cisplatin & Nab Paclitaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joyce O'Shaughnessy
Melanoma (Skin)
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node…
- Trial name
- NCT00004196
- Testing
- recombinant interferon alfa, lymphangiography, Observation
- Where
- 4 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- University of Alabama at Birmingham
Stage II Breast Cancer, Stage III Breast Cancer
Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer
Molecular expression in breast cancer (BC) defines special fenotypes with different prognostic and predictive features.Since the addition of trastuzumab and lapatinib to chemotherapy, HER2 overexpressing tumors have become the…
- Trial name
- NCT01431196
- Testing
- Autologous dendritic cell vaccination
- Where
- Spain
- Volunteers
- 29 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Breast Cancer
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER…
- Trial name
- NCT00234403
- Testing
- gefitinib and fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.